The vast variety of tumors makes each cancer a world. For researchers, understanding the commonalities and divergences in their molecular underpinnings could help find successful treatments. Scientists from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) have addressed these similarities and differences in 10 different types of cancer with two proteogenomic studies to unravel the genes that lead to cancer and the galaxy of interactions that regulate them. Read More
Boston Immune Technologies and Therapeutics Inc. (BITT) has received IND clearance from the FDA for a first-in-human trial of BITT-2101, a monoclonal antibody that targets tumor necrosis factor receptor 2 (TNFR2), in patients with relapsed or refractory non-Hodgkin lymphomas (NHLs). Read More
Methylthioadenosine phosphorylase (MTAP) is an enzyme ubiquitously expressed in all tissues. MTAP homozygous deletion occurs in 10-15% of different cancers such as leukemia, lymphoma, lung, brain, breast and others. Read More
3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD). Read More
Shanghai Haihe Biopharma Co. Ltd. has disclosed phosphonic acid derivatives and their prodrugs reported to be useful for the treatment of cancer and infections. Read More
The vitamin D receptor (VDR) is a member of the nuclear receptor superfamily and a potential target for treating hepatic fibrosis. Several VDR agonists, classified as “secosteroidal” and “non-secosteroidal,” have been developed. Read More
Silexon Intelligent Technology Co. Ltd. has synthesized heterocyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections. Read More
Redx Pharma plc has identified Rho kinase 1 (ROCK 1; p160-ROCK) and/or rho kinase 2 (ROCK 2; ROCKα) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory and neurological disorders. Read More
Methyltransferase-like 3 (METTL3) regulates mRNA translation and contributes to the most frequent modification to mRNA, the situation of a methyl group on the N6-position of A (m6A) during transcription. Read More
Gasherbrum Bio Inc. has described glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others. Read More
17-β-hydroxysteroid dehydrogenase type 10 (17-β-HSD10) catalyzes the turnover of steroids and neurosteroids, among other substrates, and is also a structural component of RNase P. 17-β-HSD10 is involved in the development of several pathologies, and considered a potential drug target for Alzheimer’s disease and some hormone-dependent cancers. A few 17-β-HSD10 inhibitors with either pyrazole, steroids, or benzothiazolylurea structure have been previously developed. Read More
